Track 10: Challenges in Rare Diseases Treatment

There are around 7,000 rare diseases, which from a regulatory outlook are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Orphan drugs are medicinal products envisioned for diagnosis, prevention, and treatment of life-threatening rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.

 

    Related Conference of Track 10: Challenges in Rare Diseases Treatment

    January 27-28, 2020

    3rd Global Experts Meeting on Infectious Diseases

    Bangkok, Thailand
    February 10-11, 2020

    2nd Global Experts Meet on STD-AIDS and Infectious Diseases

    Sydney, Australia
    February 24-25, 2020

    13thWorld Congress on Virology and Infectious Diseases

    Tokyo, Japan
    February 24-25, 2020

    7th International Congress on Infectious Diseases

    Berlin, Germany
    March 11-12, 2020

    8th International Conference on HIV AIDS STD & STIs

    Barcelona, Spain
    April 27-28, 2020

    7th Global Congress on Rare Diseases & Orphan Drug

    Istanbul, Turkey
    July 22-23, 2020

    10th World Congress on Rare Diseases and Orphan Drugs

    Barcelona, Spain
    August 19-20, 2020

    European Summit on HIV, STD and STIs

    Milan, Italy
    September 28-29, 2020

    13th Global Infections Conference

    Singapore
    October 5-6, 2020

    12th Euro-Global Conference on Infectious Diseases

    Vienna, Austria
    November 25-26, 2020

    Intercontinental Conference on Infectious Diseases

    Tokyo, Afghanistan

    Track 10: Challenges in Rare Diseases Treatment Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in